KR20140069225A - 림프종 치료에 있어서의 로미뎁신 및 5-아자사이티딘의 용도 - Google Patents

림프종 치료에 있어서의 로미뎁신 및 5-아자사이티딘의 용도 Download PDF

Info

Publication number
KR20140069225A
KR20140069225A KR1020147010755A KR20147010755A KR20140069225A KR 20140069225 A KR20140069225 A KR 20140069225A KR 1020147010755 A KR1020147010755 A KR 1020147010755A KR 20147010755 A KR20147010755 A KR 20147010755A KR 20140069225 A KR20140069225 A KR 20140069225A
Authority
KR
South Korea
Prior art keywords
azacytidine
day
administered
days
romipeptin
Prior art date
Application number
KR1020147010755A
Other languages
English (en)
Korean (ko)
Inventor
라인하드 더머
시마 로자티
Original Assignee
셀진 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀진 코포레이션 filed Critical 셀진 코포레이션
Publication of KR20140069225A publication Critical patent/KR20140069225A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147010755A 2011-09-23 2012-09-21 림프종 치료에 있어서의 로미뎁신 및 5-아자사이티딘의 용도 KR20140069225A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161538734P 2011-09-23 2011-09-23
US61/538,734 2011-09-23
US201261698441P 2012-09-07 2012-09-07
US61/698,441 2012-09-07
PCT/US2012/056485 WO2013043967A1 (en) 2011-09-23 2012-09-21 Romidepsin and 5 - azacitidine for use in treating lymphoma

Publications (1)

Publication Number Publication Date
KR20140069225A true KR20140069225A (ko) 2014-06-09

Family

ID=47045157

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147010755A KR20140069225A (ko) 2011-09-23 2012-09-21 림프종 치료에 있어서의 로미뎁신 및 5-아자사이티딘의 용도

Country Status (12)

Country Link
US (1) US20130085115A1 (zh)
EP (1) EP2758067A1 (zh)
JP (1) JP2014526558A (zh)
KR (1) KR20140069225A (zh)
CN (1) CN104114182A (zh)
AU (1) AU2012312308B2 (zh)
CA (1) CA2849708A1 (zh)
HK (1) HK1200330A1 (zh)
IL (1) IL231636A0 (zh)
MX (1) MX2014003467A (zh)
WO (1) WO2013043967A1 (zh)
ZA (1) ZA201402151B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195634A1 (en) * 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
EP3481404A4 (en) * 2016-07-07 2020-03-25 Miragen Therapeutics, Inc. METHOD FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL) WITH MIR-155 INHIBITORS

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH064872A (ja) 1992-06-19 1994-01-14 Sony Corp 光ディスク再生装置
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US7396665B2 (en) 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
EP1482418A1 (en) 2003-05-28 2004-12-01 Sap Ag A data processing method and system
JP2009532346A (ja) * 2006-03-31 2009-09-10 イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム 腫瘍増殖制御のための新規組成物
WO2007145704A2 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US20110269699A1 (en) * 2008-10-24 2011-11-03 Mitchell Keegan Cancer therapy

Also Published As

Publication number Publication date
JP2014526558A (ja) 2014-10-06
HK1200330A1 (zh) 2015-08-07
IL231636A0 (en) 2014-05-28
CN104114182A (zh) 2014-10-22
AU2012312308A1 (en) 2013-05-02
WO2013043967A1 (en) 2013-03-28
EP2758067A1 (en) 2014-07-30
NZ622752A (en) 2016-06-24
US20130085115A1 (en) 2013-04-04
AU2012312308B2 (en) 2015-11-19
ZA201402151B (en) 2015-06-24
MX2014003467A (es) 2014-07-30
CA2849708A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
KR101633134B1 (ko) 시티딘 유사체의 경구 제형 및 그의 사용 방법
RU2543348C2 (ru) Способ лечения путем применения комбинированной терапии
JP6063628B2 (ja) ５−アザシチジンを用いる、非小細胞肺癌の治療方法
JP6162709B2 (ja) シチジンアナログの経口製剤を使用して癌を治療する方法
KR20170045237A (ko) 항-pd1 또는 항-pdl1 단클론성 항체와 조합된 시티딘 유사체의 경구 제제를 사용한 질환 또는 장애를 치료하는 방법
AU2013202507B2 (en) Inhibition of drug resistant cancer cells
JP5948332B2 (ja) Ｍｌｌ再構成白血病の治療法
KR20140069225A (ko) 림프종 치료에 있어서의 로미뎁신 및 5-아자사이티딘의 용도
AU2012316266B2 (en) Combination therapy for chemoresistant cancers
NZ622752B2 (en) Romidepsin and 5 - azacitidine for use in treating lymphoma
AU2009230499B2 (en) Anti-tumor agent comprising cytidine derivative and carboplatin
WO2020090698A1 (ja) 医薬組成物

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid